Literature DB >> 26627827

Epiregulin Recognition Mechanisms by Anti-epiregulin Antibody 9E5: STRUCTURAL, FUNCTIONAL, AND MOLECULAR DYNAMICS SIMULATION ANALYSES.

Yuji Kado1, Eiichi Mizohata2, Satoru Nagatoishi3, Mariko Iijima4, Keiko Shinoda4, Takamitsu Miyafusa3, Taisuke Nakayama2, Takuma Yoshizumi2, Akira Sugiyama4, Takeshi Kawamura4, Young-Hun Lee4, Hiroyoshi Matsumura2, Hirofumi Doi4, Hideaki Fujitani4, Tatsuhiko Kodama4, Yoshikazu Shibasaki4, Kouhei Tsumoto5, Tsuyoshi Inoue6.   

Abstract

Epiregulin (EPR) is a ligand of the epidermal growth factor (EGF) family that upon binding to its epidermal growth factor receptor (EGFR) stimulates proliferative signaling, especially in colon cancer cells. Here, we describe the three-dimensional structure of the EPR antibody (the 9E5(Fab) fragment) in the presence and absence of EPR. Among the six complementarity-determining regions (CDRs), CDR1-3 in the light chain and CDR2 in the heavy chain predominantly recognize EPR. In particular, CDR3 in the heavy chain dramatically moves with cis-trans isomerization of Pro(103). A molecular dynamics simulation and mutational analyses revealed that Arg(40) in EPR is a key residue for the specific binding of 9E5 IgG. From isothermal titration calorimetry analysis, the dissociation constant was determined to be 6.5 nm. Surface plasmon resonance analysis revealed that the dissociation rate of 9E5 IgG is extremely slow. The superimposed structure of 9E5(Fab)·EPR on the known complex structure of EGF·EGFR showed that the 9E5(Fab) paratope overlaps with Domains I and III on the EGFR, which reveals that the 9E5(Fab)·EPR complex could not bind to the EGFR. The 9E5 antibody will also be useful in medicine as a neutralizing antibody specific for colon cancer.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  antibody; cancer; crystal structure; epidermal growth factor (EGF); molecular dynamics; thermodynamics

Mesh:

Substances:

Year:  2015        PMID: 26627827      PMCID: PMC4732215          DOI: 10.1074/jbc.M115.656009

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

1.  Structure validation by Calpha geometry: phi,psi and Cbeta deviation.

Authors:  Simon C Lovell; Ian W Davis; W Bryan Arendall; Paul I W de Bakker; J Michael Word; Michael G Prisant; Jane S Richardson; David C Richardson
Journal:  Proteins       Date:  2003-02-15

2.  Canonical dynamics: Equilibrium phase-space distributions.

Authors: 
Journal:  Phys Rev A Gen Phys       Date:  1985-03

3.  Involvement of deregulated epiregulin expression in tumorigenesis in vivo through activated Ki-Ras signaling pathway in human colon cancer cells.

Authors:  I Baba; S Shirasawa; R Iwamoto; K Okumura; T Tsunoda; M Nishioka; K Fukuyama; K Yamamoto; E Mekada; T Sasazuki
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

4.  GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit.

Authors:  Sander Pronk; Szilárd Páll; Roland Schulz; Per Larsson; Pär Bjelkmar; Rossen Apostolov; Michael R Shirts; Jeremy C Smith; Peter M Kasson; David van der Spoel; Berk Hess; Erik Lindahl
Journal:  Bioinformatics       Date:  2013-02-13       Impact factor: 6.937

5.  Substitution of lysine for arginine at position 42 of human transforming growth factor-alpha eliminates biological activity without changing internal disulfide bonds.

Authors:  D Defeo-Jones; J Y Tai; G A Vuocolo; R J Wegrzyn; T L Schofield; M W Riemen; A Oliff
Journal:  Mol Cell Biol       Date:  1989-09       Impact factor: 4.272

6.  Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4.

Authors:  T Komurasaki; H Toyoda; D Uchida; S Morimoto
Journal:  Oncogene       Date:  1997-12-04       Impact factor: 9.867

7.  Construction and characterization of functional anti-epiregulin humanized monoclonal antibodies.

Authors:  Young-Hun Lee; Mariko Iijima; Yuji Kado; Eiichi Mizohata; Tsuyoshi Inoue; Akira Sugiyama; Hirofumi Doi; Yoshikazu Shibasaki; Tatsuhiko Kodama
Journal:  Biochem Biophys Res Commun       Date:  2013-11-12       Impact factor: 3.575

8.  Critical functional requirement for the guanidinium group of the arginine 41 side chain of human epidermal growth factor as revealed by mutagenic inactivation and chemical reactivation.

Authors:  D A Engler; S R Campion; M R Hauser; J S Cook; S K Niyogi
Journal:  J Biol Chem       Date:  1992-02-05       Impact factor: 5.157

Review 9.  Interactions of protein antigens with antibodies.

Authors:  D R Davies; G H Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

10.  Towards automated crystallographic structure refinement with phenix.refine.

Authors:  Pavel V Afonine; Ralf W Grosse-Kunstleve; Nathaniel Echols; Jeffrey J Headd; Nigel W Moriarty; Marat Mustyakimov; Thomas C Terwilliger; Alexandre Urzhumtsev; Peter H Zwart; Paul D Adams
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2012-03-16
View more
  5 in total

1.  Selective intracellular delivery of perfluorocarbon nanodroplets for cytotoxicity threshold reduction on ultrasound-induced vaporization.

Authors:  Ayumu Ishijima; Satoshi Yamaguchi; Takashi Azuma; Etsuko Kobayashi; Yoshikazu Shibasaki; Teruyuki Nagamune; Ichiro Sakuma
Journal:  Cancer Rep (Hoboken)       Date:  2019-02-17

2.  Functional EGF domain of the human neuregulin 1α produced in Escherichia coli with accurate disulfide bonds.

Authors:  Arthur Schveitzer Ferreira; Amanda Lopacinski; Michel Batista; Priscila Mazzocchi Hiraiwa; Natalia Fernanda Bueno; Beatriz Gomes Guimarães; Nilson I T Zanchin
Journal:  Mol Biol Rep       Date:  2022-10-05       Impact factor: 2.742

3.  Initiation of prolyl cis-trans isomerisation in the CDR-H3 loop of an antibody in response to antigen binding.

Authors:  Keiko Shinoda; Hideaki Fujitani
Journal:  Sci Rep       Date:  2017-12-05       Impact factor: 4.379

4.  Selective intracellular vaporisation of antibody-conjugated phase-change nano-droplets in vitro.

Authors:  A Ishijima; K Minamihata; S Yamaguchi; S Yamahira; R Ichikawa; E Kobayashi; M Iijima; Y Shibasaki; T Azuma; T Nagamune; I Sakuma
Journal:  Sci Rep       Date:  2017-03-23       Impact factor: 4.379

5.  A toolkit for recombinant production of seven human EGF family growth factors in active conformation.

Authors:  Arthur Schveitzer Ferreira; Amanda Lopacinski; Michel Batista; Priscila Mazzocchi Hiraiwa; Beatriz Gomes Guimarães; Nilson Ivo Tonin Zanchin
Journal:  Sci Rep       Date:  2022-03-23       Impact factor: 4.996

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.